N-(3-(3-(4-(1-Aminocyclobutyl)phenyl)-2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-5-yl)phenethyl)-7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptanamide

ID: ALA5219172

Chembl Id: CHEMBL5219172

PubChem CID: 139483312

Max Phase: Preclinical

Molecular Formula: C49H50N10O5

Molecular Weight: 859.00

Associated Items:

Names and Identifiers

Canonical SMILES:  Nc1ncccc1-c1nc2ccc(-c3cccc(CCNC(=O)CCCCCCNc4cccc5c4C(=O)N(C4CCC(=O)NC4=O)C5=O)c3)nc2n1-c1ccc(C2(N)CCC2)cc1

Standard InChI:  InChI=1S/C49H50N10O5/c50-43-35(12-7-27-54-43)44-56-38-20-19-36(55-45(38)58(44)33-17-15-32(16-18-33)49(51)24-8-25-49)31-10-5-9-30(29-31)23-28-53-40(60)14-3-1-2-4-26-52-37-13-6-11-34-42(37)48(64)59(47(34)63)39-21-22-41(61)57-46(39)62/h5-7,9-13,15-20,27,29,39,52H,1-4,8,14,21-26,28,51H2,(H2,50,54)(H,53,60)(H,57,61,62)

Standard InChI Key:  FNQYBWOHCJISHF-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA5219172

    ---

Associated Targets(Human)

AKT1 Tchem CRBN/AKT1 (26 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 859.00Molecular Weight (Monoisotopic): 858.3966AlogP: 6.19#Rotatable Bonds: 16
Polar Surface Area: 220.32Molecular Species: BASEHBA: 12HBD: 5
#RO5 Violations: 3HBA (Lipinski): 15HBD (Lipinski): 7#RO5 Violations (Lipinski): 4
CX Acidic pKa: 11.59CX Basic pKa: 9.65CX LogP: 5.67CX LogD: 3.59
Aromatic Rings: 6Heavy Atoms: 64QED Weighted: 0.05Np Likeness Score: -0.63

References

1. Yu X, Xu J, Cahuzac KM, Xie L, Shen Y, Chen X, Liu J, Parsons RE, Jin J..  (2022)  Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells.,  65  (20.0): [PMID:36197750] [10.1021/acs.jmedchem.2c01454]

Source